www.clovisoncology.com
| Three Rubraca (Rucaparib) indications: - Rubraca is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic) associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane- based chemotherapy.
- Rubraca tablets are indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Rubraca is indicated for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA- approved companion diagnostic for Rubraca.
HCP Approval Announcement
Beyond BRCA Rubraca
Maintenance Matters Rubraca | 
Virtual Drop In:Friday, July 8 2:00-2:30
Access: <link to webinar> |
Facebook
Twitter
LinkedIn
Forward